38 results about "Clostridium perfringens infection" patented technology

The invention discloses recombinant epsilon protein for inhibiting clostridium perfringens infection and a preparation method and application thereof. The recombinant epsilon protein is (a) protein formed by amino acid sequences shown in SEQ ID No.2 or (b) protein formed by amino acid sequences from the 51 site to the 370 site in SEQ ID No.2 or fusion protein obtained by fusing protein tags on carboxyl terminals or / and amino terminals of the (a) protein or the (b) protein. After animals are immune to the recombinant epsilon protein, the animals can generate the high serum antibody level and can resist attack of clostridium perfringens. The recombinant epsilon protein is good in dissolvability and easy to purify and can be taken as a diagnostic antigen or prepared into a monoclonal antibody or used for further studying the protein function and the conformation relationship.

The invention discloses a recombinant lactobacillus for simultaneously expressing clostridium perfringens alpha, beta 2, epsilon and beta 1 exotoxin, a construction method of the recombinant lactobacillus and an application. The recombinant lactobacillus takes the clostridium perfringens alpha, beta 1, beta 2 and epsilon exotoxin reconstructed from gene levels in a toxicity removal manner as immunogen, the reconstructed exotoxin completely loses pathogenicity and still retains immunogenicity, and the lactobacillus serves as a safe living bacterium carrier for transmitting and expressing immunizing antigens, so that the recombinant lactobacillus capable of simultaneously expressing clostridium perfringens alpha, beta 2, epsilon and beta 1 exotoxin is acquired, and a gene engineering lactobacillus multi-valence subunit toxin oral immune preparation capable of effectively preventing infection of five serotype clostridium perfringens is prevented. The recombinant lactobacillus provides effective technical means for preventing infection of the clostridium perfringens.

The invention discloses a ssc-miR-122-5p related to piglet type C Clostridium perfringens infectious diarrhea, the nucleotide sequence of the ssc-miR-122-5p is shown in SEQ ID NO.1 . The present invention also discloses specific primers for detecting the expression level of ssc-miR-122-5p, the sequence of which is shown in SEQ ID NO.2. The invention discloses a method for improving piglet resistance to type C Clostridium perfringens infection by interfering with ssc-miR-122-5p. The present invention found for the first time that ssc-miR-122-5p was significantly highly expressed in the ileum tissue of piglets with Clostridium perfringens type C infectious diarrhea, and then IPEC-J2 cells were used as the research object to overexpress and interfere with ssc-miR ‑122‑5p studied its effect on CPB2 toxin-induced IPEC‑J2 cell damage, in order to elucidate the mechanism of ssc‑miR‑122‑5p involved in the regulation of diarrhea caused by Clostridium perfringens type C infection, which is a bacterium in piglets Molecular breeding of sexual diarrhea provides a powerful scientific reference.

The present invention relates to generation and high level expression of recombinant non-toxic of epsilon toxin of Clostridium perfringens as a recombinant vaccine against Clostridium perfringens infection and a process for producing the vaccine involving amplifying, cloning, transforming, incubating and purifying the recombinant non-toxic epsilon toxin protein. Thus in this invention, substitution mutation Y71G was executed in recombinant Etx and the recombinant EtxY71G protein was over-expressed in soluble form. Expressed protein was purified near homogeneity by DEAE sepharose anion exchange chromatography with high yield. Potential of rEtxY71G as a vaccine candidate was evaluated and found to be highly specific and immunogenic. The present invention is the first report for high level expression of non toxic rEtxY71G mutant protein of Clostridium perfringens. Upto 100 mg / L of highly immunogenic and homogeneous recombinant EtxY71G protein of 31 kDa was produced. Further, the immunization with rEtxY71G gave very high titer and conferred protection against epsilon toxin intoxication.

The invention discloses a preparation method of fusion protein for inhibiting clostridium perfringens infection. The method comprises the step that encoding genes of protein are expressed in organisms to obtain the fusion protein, wherein the organisms are microorganisms or plants or non-human animals; the protein is shown in (a) or (b) or (c), wherein the protein in (a) is composed of amino acid sequences shown as SEQ ID No.2; the protein in (b) is composed of amino acid sequences shown at the sites No.51-No.937 of SEQ ID No.2; the fusion protein in (c) is obtained by fusing protein tags at carboxyl terminals or / and amino terminals of the protein shown in (a) or (b). The fusion protein prepared through the method is good in solubility and easy to purify and can serve as a diagnostic antigen to be prepared into a monoclonal antibody or be used for further research on protein functions and conformation relations.